Sugi Predict

Sugi Predict / Targets / PARP11

PARP11

Protein mono-ADP-ribosyltransferase PARP11 · Q9NR21 · PARP11 on Sugi Atlas →

18,127 patent compounds predicted against PARP11, 11,890 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1759917 SCHEMBL1759917 0.50 11/20
SCHEMBL793156 SCHEMBL793156 0.72 10/20
SCHEMBL1432009 SCHEMBL1432009 0.63 10/20
SCHEMBL1432600 SCHEMBL1432600 0.63 10/20
SCHEMBL1725257 SCHEMBL1725257 0.59 10/20
SCHEMBL1725258 SCHEMBL1725258 0.58 10/20
SCHEMBL1727568 SCHEMBL1727568 0.58 10/20
SCHEMBL1724184 SCHEMBL1724184 0.56 10/20
SCHEMBL393532 SCHEMBL393532 0.56 10/20
SCHEMBL1726500 SCHEMBL1726500 0.55 10/20
SCHEMBL1636716 SCHEMBL1636716 0.54 10/20
SCHEMBL279903 SCHEMBL279903 1.00 9/20
SCHEMBL831538 SCHEMBL831538 1.00 9/20
SCHEMBL1002712 SCHEMBL1002712 1.00 9/20
SCHEMBL1727165 SCHEMBL1727165 0.72 9/20
SCHEMBL794160 SCHEMBL794160 0.69 9/20
SCHEMBL1315035 SCHEMBL1315035 0.69 9/20
SCHEMBL1417646 SCHEMBL1417646 0.64 9/20
SCHEMBL279822 SCHEMBL279822 0.63 9/20
SCHEMBL379341 SCHEMBL379341 0.63 9/20

Clinical trials — most relevant to PARP11 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients PHASE3COMPLETED
Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) PHASE2RECRUITING
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies PHASE1/PHASE2RECRUITING
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA) PHASE1/PHASE2COMPLETED
A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib PHASE2COMPLETED
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer PHASE2ACTIVE_NOT_RECRUITING
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations PHASE1/PHASE2COMPLETED
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma PHASE2COMPLETED
Olaparib In Metastatic Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Phase II ABT-888 With Cyclophosphamide PHASE2COMPLETED
Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer PHASE2COMPLETED
Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor PHASE2COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer PHASE1COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer PHASE1UNKNOWN
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers PHASE1COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors PHASE1COMPLETED
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults PHASE1RECRUITING
Pre-Operative Radiation and Veliparib for Breast Cancer PHASE1COMPLETED
Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors PHASE1COMPLETED
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer PHASE1ACTIVE_NOT_RECRUITING
ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems PHASE1WITHDRAWN
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts PHASE1ACTIVE_NOT_RECRUITING
Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma PHASE1ACTIVE_NOT_RECRUITING
ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors PHASE1WITHDRAWN
PET Imaging of PARP Activity in Cancer EARLY_PHASE1UNKNOWN
Sirtuin1 in COVID19 Patients nanUNKNOWN
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer nanNO_LONGER_AVAILABLE

Related proteins — ESM-2 sequence neighbours (a PARP11 binder may also engage these)

ProteinNameSimilarity
Q8CFF0 — 1.000 Q8CFF0 →
PARP4 Protein mono-ADP-ribosyltransferase PARP4 0.960 landscape →
TIPARP Protein mono-ADP-ribosyltransferase TIPARP 0.960 landscape →
Q9BXB4 — 0.958 Q9BXB4 →
Q9BXW6 — 0.958 Q9BXW6 →
Q8K4M9 — 0.958 Q8K4M9 →
Q91XL9 — 0.957 Q91XL9 →
Q6DC04 — 0.956 Q6DC04 →
Q8BZ20 — 0.956 Q8BZ20 →
Q6DD21 — 0.956 Q6DD21 →
Q8N1G2 — 0.956 Q8N1G2 →
Q8C1B2 — 0.956 Q8C1B2 →
Q9UPW5 — 0.956 Q9UPW5 →
SHPRH E3 ubiquitin-protein ligase SHPRH 0.955 landscape →
P62205 — 0.955 P62205 →
Q5ZJX5 — 0.955 Q5ZJX5 →
Q5ZJJ5 — 0.955 Q5ZJJ5 →
PARP9 Protein mono-ADP-ribosyltransferase PARP9 0.955 landscape →
PARP12 Protein mono-ADP-ribosyltransferase PARP12 0.955 landscape →
Q8CI95 — 0.955 Q8CI95 →
Q5R981 — 0.955 Q5R981 →
Q5U2Q4 — 0.954 Q5U2Q4 →
Q641K1 — 0.954 Q641K1 →
Q7TMM8 — 0.954 Q7TMM8 →
Q3ULW8 — 0.954 Q3ULW8 →
Q9DBC3 — 0.954 Q9DBC3 →
Q5JPI3 — 0.954 Q5JPI3 →
Q8NHP6 — 0.954 Q8NHP6 →
Q7TPQ3 — 0.953 Q7TPQ3 →
Q8IZC4 — 0.953 Q8IZC4 →